Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer

• Published in: Einstein (São Paulo, Brazil) Brazil), 2019-01, Vol.17 (1), p.eAO3434-eAO3434
• Main Authors: Silva, Luana Carolina Ferreira Fiuza, Arruda, Lilian Silva Martins de, David Filho, Waldec Jorge, Cruz, Felipe José Silva Melo, Trufelli, Damila Cristina, Del Giglio, Auro
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Analysis of Variance; Breast Neoplasms - chemistry; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Carcinoma - chemistry; Carcinoma - drug therapy; Carcinoma - mortality; Carcinoma - pathology; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; MEDICINE, GENERAL & INTERNAL; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy - methods; Neoplasias da mama/patologia; Original; Predictive Value of Tests; Prognóstico; Receptors, Estrogen - analysis; Receptors, Progesterone - analysis; Reference Values; Retrospective Studies; Risk Factors; Sobrevivência (Saúde Pública); Terapia neoadjuvante; Time Factors; Treatment Outcome; Valor preditivo dos testes
• ISSN: 1679-4508; 2317-6385; 2317-6385
• DOI: 10.31744/einstein_journal/2019AO3434

To define a predictive factor for pathologic complete response, compare the oncologic outcomes associated with the degree of pathologic response after neoadjuvant chemotherapy, and to analyze pathologic complete response as a prognostic factor for overall survival and progression-free survival. A retrospective study of patients admitted to Hospital Estadual Mário Covas and Hospital Anchieta from 2008 to 2012, with locally advanced breast cancer. Hormone receptor status, HER2 status, histologic and nuclear grade, age upon diagnosis and histological type of the tumor were analyzed. Pathologic evaluation of the tumor was subdivided into pathologic complete response, defined by the absence of tumor; intermediate response, considered as a favorable stage; and poor response, considering low-responder patients. Data obtained were submitted to statistical analysis. The study included 243 patients. There was an association of pathologic complete response with HER-2 negative, histological grade 3, stage III, hormone receptor negative, positive lymph node, older age and more advanced tumors. However, after multivariate analysis the only predictor of pathologic complete response was the presence of negative hormone receptor. By analyzing the prognostic factors, hormone receptor negative was considered as an independent risk factor, and pathologic complete response was considered as an independent protective factor. Hormone receptor negative is predictive of pathologic complete response and is an isolated risk factor for lower progression-free survival and overall survival. Pathologic complete response is a protective factor for these same survival analyses.